$AHCO

SAMET KENNETH A purchased $150K of AHCO

SAMET KENNETH A purchased 23,500 shares of AdaptHealth Corp. (AHCO) at $6.38 ($0.15M total) on 2026-08-06.

Original reporting
SEC EDGAR · SAMET KENNETH A
Published Aug 11, 2026, 12:03 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 11, 2026, 12:04 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$AHCO
Bullish
medium confidence
Mentioned
$AHCO
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AHCOBullishLow
01

Why it matters

A director open-market purchase of $149,930 worth of shares was reported, but the filing contains no new company fundamentals such as earnings, guidance, contracts, or regulatory actions.

02

Market read

Traders may view the director buy as a small sentiment tailwind, but it is unlikely to drive a durable repricing without additional fundamental catalysts.

03

What to watch

The article provides no context on whether the director’s buy is part of a broader pattern, nor any concurrent company news that would validate the signal.

Relevance 5/10Novelty 5/10Timing: filed Aug 10, transaction dated Aug 6

Background

This is an SEC Form 4 insider transaction disclosure for AdaptHealth Corp. (AHCO).

Company-level read

Ticker impact

$AHCOBullishMedium confidence
Context

AdaptHealth (AHCO) disclosed an insider open-market purchase by director Samet Kenneth A of 23,500 shares at $6.38.

Expected impact

Likely limited near-term impact; any effect is sentiment-driven and typically fades unless followed by additional disclosures.

Evidence & confidence

Form 4 insider buys can signal confidence, but this is a single director transaction with no accompanying guidance, deal, or operational change in the text.

Market effects

No sector-wide implications are stated; this is a company-specific insider transaction.

None indicated.

None indicated.

Counterpoint

Insider buys can be routine or driven by personal liquidity planning, and the absence of a 10b5-1 plan does not guarantee a strong directional signal.

Key entities

  • AdaptHealth Corp.

    Subject of the Form 4 insider transaction disclosure (AHCO).

  • SAMET KENNETH A

    Director who purchased 23,500 shares at $6.38 on 2026-08-06.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AHCOMedAI 8/10

AdaptHealth Cuts 2026 Outlook as Contract Costs Hit Margins

AdaptHealth Corp. (AHCO) cut its 2026 adjusted EBITDA outlook to $490 million to $520 million from $680 million to $730 million, citing margin pressure from West Coast capitated contract costs and a manufacturer price increase. Revenue guidance is $2.85 billion to $2.89 billion. Q2 organic revenue rose 15.9% to $740.3 million. The company agreed to sell Diabetes Health for $235 million.

$AHCOHighAI 9/10

AdaptHealth (AHCO) Q2 2026 Earnings Call Transcript

AdaptHealth (AHCO) reported Q2 2026 net revenue of $740.3 million, up 12.7% year over year, with organic revenue growth of 15.9%. Adjusted EBITDA was $132 million, down 3.2%, and full-year revenue guidance was cut to $2.85-$2.89 billion with adjusted EBITDA of $490-$520 million. The company cited West Coast contract costs and a $30 million supplier price headwind, plus a $235 million diabetes divestiture.

$AHCOMed

AdaptHealth Sells Diabetes Unit to Sharpen Focus on Sleep, Respiratory Growth

AdaptHealth (NASDAQ:AHCO) said it will sell its diabetes unit to focus on sleep and respiratory. The deal is expected to leave about $60 million of overhead costs in continuing operations, with roughly half removed in year one. Q2 revenue grew 16%, including West Coast expansion, while the company works on contract onboarding and supplier rebate terms.

$AHCOHighAI 9/10

Why AdaptHealth Stock Plummeted This Week

AdaptHealth (NASDAQ: AHCO) shares fell about 47% this week after the company reported Q2 results below expectations and issued sharply lower guidance. Analysts expected EPS of $0.15; AdaptHealth posted a loss of $1.07 per share. Sales rose 12.7% to $740.3M but missed forecasts. Full-year sales guidance was cut to $2.85B-$2.89B and EBITDA and FCF ranges were reduced.

$AHCOHighAI 9/10

AdaptHealth Shares Sink After Earnings Miss and Lower Full-Year Guidance

AdaptHealth Corp. (NASDAQ:AHCO) shares fell about 13% premarket after Q2 2026 results missed expectations and the company cut full-year guidance. It reported a net loss of $0.99 per share and revenue of $740.3M versus $848.9M expected. FY revenue guidance was lowered to $2.85B-$2.89B from about $3.49B, with adjusted EBITDA $490M-$520M and free cash flow $80M-$120M.